irinotecan

From an initial pool of 1345 articles, 11 relevant studies were selected for inclusion, encompassing a diverse range of systemic treatments, including panitumumab combined with FOLFOX4 and FOLFIRI, irinotecan paired with panitumumab, regorafenib followed by cetuximab ± irinotecan and vice versa, and panitumumab as a maintenance therapy post-induction...Notably, cetuximab + FOLFIRI was associated with a median survival of 25.7 months versus 16.4 months for FOLFIRI alone, emphasizing the potential benefits of integrating targeted therapies with chemotherapy. In conclusion, the review underscores the significant impact of systemic treatments, particularly targeted therapies and their combinations with chemotherapy, on survival outcomes and QoL in patients with RAS-positive stage IV colorectal cancer, and the need for personalized treatment.

P2, N=260, Recruiting, Genentech, Inc. | Trial completion date: May 2029 --> Dec 2029 | Trial primary completion date: May 2029 --> Dec 2029

Combination treatment with leucovorin and oxaliplatin or irinotecan improves the effectiveness of 5FU therapy. In vitro assays with human colon cancer cell lines showed that therapy with TcES+5FU significantly reduced cell proliferation and migration by modulating the P53 and P21 signaling pathways. Our findings demonstrate, for the first time in vivo, that helminth-derived excreted/secreted products may potentiate the effect of 5FU on established colon tumors.

P1/2, N=1126, Recruiting, Amgen | Trial primary completion date: Sep 2026 --> Dec 2026

P1/2, N=22, Terminated, Memorial Sloan Kettering Cancer Center | Completed --> Terminated; Due to DLTs

We first constructed molecular subtypes and prognostic models related to O-glycan biosynthesis in PC. It is clear that O-glycan biosynthesis is related to the development, prognosis, immune microenvironment, and treatment of PC. This provides new strategies for stratification, diagnosis, and treatment of PC patients.

P2, N=66, Completed, Luye Pharma Group Ltd. | Active, not recruiting --> Completed

P1/2, N=90, Recruiting, Alligator Bioscience AB | Active, not recruiting --> Recruiting | Phase classification: P1b/2 --> P1/2 | Trial primary completion date: Feb 2024 --> Feb 2025

P1/2, N=78, Enrolling by invitation, Luye Pharma Group Ltd. | Trial completion date: Oct 2023 --> Oct 2024 | Trial primary completion date: Aug 2023 --> Aug 2024

P1/2, N=66, Not yet recruiting, Amsterdam UMC, location VUmc

Co-assembling of the glycosylated peptide with two counterparts containing irinotecan (IRI) or ligand TSFAEYWNLLSP (PMI) results in formation of the glycosylated co-assemblies SgVEIP, which target cancer cells via β-galactose-galectin-1 association and undergo galactosidase-induced morphological transformation...In vivo studies illustrate enhanced tumor accumulation and retention of the glycosylated co-assemblies, thereby suppressing tumor growth. Our findings demonstrate an in situ assembly strategy mimicking viral infection, thus providing a new route for drug delivery and cancer therapy in the future.

P2, N=25, Not yet recruiting, Mayo Clinic

P1, N=78, Active, not recruiting, Symphogen A/S | N=148 --> 78 | Trial completion date: Jan 2025 --> Jun 2024

P2, N=60, Active, not recruiting, Salspera LLC | Recruiting --> Active, not recruiting

P=N/A, N=647, Completed, iOMEDICO AG | Active, not recruiting --> Completed

This phenotype/genotype investigation suggests that the FGFR4 p.G388R variant may serve as a new marker for identifying patients who are responsive to TAS-102. A mechanistic hypothesis is proposed to interpret these findings.

P3, N=668, Ongoing, 1Globe Health Institute

P2, N=150, Recruiting, Leap Therapeutics, Inc. | Trial completion date: Aug 2024 --> Dec 2025 | Trial primary completion date: Mar 2024 --> Dec 2025

In the first line, all patients received bi-chemotherapy plus bevacizumab, i.e., fluorouracil, oxaliplatin, and leucovorin in 34 (20.9%) patients; capecitabine plus oxaliplatin in 88 (54.3%) patients; leucovorin, fluorouracil, and irinotecan in 17 (10.4%) patients; and capecitabine plus irinotecan in 23 (14.1%) patients. With the new healthcare and social security systems, easier access to expensive treatments and molecular pathology tests is currently available. It is important to highlight that real-world data can offer valuable insights into the daily clinical practice of medical oncology.

P1, N=282, Recruiting, Amgen | Not yet recruiting --> Recruiting

P1, N=62, Completed, Bayer | Active, not recruiting --> Completed

P3, N=408, Recruiting, ECOG-ACRIN Cancer Research Group | Not yet recruiting --> Recruiting

The FOLFOXIRI plus cetuximab regimen displayed tolerable toxicity and promising anti-tumor activity in terms of the rate of NED achieved and response rate in patients with initially unresectable left-sided RAS/BRAF wild-type CLM. This regimen merits further investigation.

P2, N=77, Active, not recruiting, Seoul National University Hospital | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2024

P2, N=71, Recruiting, University of Wisconsin, Madison | N=110 --> 71

P4, N=642, Not yet recruiting, Health Science Center of Xi'an Jiaotong University

P2, N=55, Active, not recruiting, MedSIR | Trial completion date: Mar 2024 --> Jun 2025

P2, N=40, Recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Patients received anti-EGFR rechallenge therapy, including cetuximab plus avelumab, trifluridine-tipiracil plus panitumumab, irinotecan plus cetuximab, or panitumumab monotherapy. Within the limitation of a subgroup analysis, the absence of liver metastases was associated with significant improved survival. ClinicalTrials.gov Identifiers: NCT02296203; NCT04561336; NCT03227926; NCT05468892.

Our novel treatment strategy delivered acceptable survival outcomes and reduced severe dermatologic toxicities.

In summary, our findings confirm that ginsenoside Rh4 can alleviate CPT-11-induced gastrointestinal mucositis and enhance the anti-tumor activity of CPT-11 by modulating gut microbiota and its related metabolites. Our study validates the potential of ginsenoside Rh4 as a modulator of the gut microbiota and an adjunctive agent for chemotherapy, offering new therapeutic strategies for addressing chemotherapy side effects and improving chemotherapy efficacy.

P2, N=60, Recruiting, OHSU Knight Cancer Institute | Trial primary completion date: Apr 2024 --> Apr 2025

P3, N=830, Completed, University of Erlangen-Nürnberg Medical School | Active, not recruiting --> Completed | Trial completion date: Aug 2026 --> Nov 2023

P1, N=282, Not yet recruiting, Amgen

P3, N=520, Active, not recruiting, Taizhou Mabtech Pharmaceutical Co.,Ltd | Trial completion date: Jun 2023 --> Jun 2024

P3, N=450, Not yet recruiting, Merck Sharp & Dohme LLC

"BACKGROUND: Systemic therapies such as fruquintinib, regorafenib, and trifluridine/tipiracil (T/T) have demon- strated survival benefits vs best supportive care (BSC) in patients with metastatic colorectal cancer (mCRC) pre- viously treated with oxaliplatin- and irinotecan-based chemotherapy (OIC)...OBJECTIVE: To compare the AE management costs of fruquin- tinib, regorafenib, T/T and T/T+bevacizumab (T/T+bev) for mCRC previously treated with OIC, from US Commercial and Medicare payer perspectives... Based on the cost-consequence model results, fruquintinib was associated with lower AE manage- ment costs compared with regorafenib, T/T, and T/T+bev for patients with mCRC previously treated with OIC, which should be considered in treatment and formulary decision- making."

We provide the in vivo evidence of the clinical prognostic implications of therapy-induced senescence. Our results revealed that STCs were responsible for CRC progression by producing large amounts of EVs enriched in SERPINE1. These findings further confirm the crucial role of therapy-induced senescence in tumor progression and offer a potential therapeutic strategy for CRC treatment.

P2, N=78, Active, not recruiting, Yonsei University

This study provides evidence for the first time that gastrodin attenuated colitis and prevented colitisrelated carcinogenesis in mice, at least partially, by diminishing tumor-promoting cytokines through the interruption of TLR4/MD2/NF-ΚB signaling transduction.

Olaparib is not a cost-effective maintenance treatment option. Companion diagnostics are an equally important cost driver as the drug itself.

P2, N=150, Active, not recruiting, University Health Network, Toronto | Recruiting --> Active, not recruiting | Trial completion date: Sep 2023 --> Sep 2026 | Trial primary completion date: Sep 2022 --> Jan 2025